Lijuan Wang

Lijuan Wang


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1998 in Transfusion
Verified
Journal Article
Closed access
PDF file
CHC. A. Hyland
C. A. Hyland
LML. Mison
L. Mison
NSN. Solomon
N. Solomon
JCJ. Cockerill
J. Cockerill
LWLijuan Wang
Lijuan Wang
EGE. J. Gowans
E. J. Gowans

18 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
RLRui Li
Rui Li
SZSha Zhou
Sha Zhou
ZGZongjie Gan
Zongjie Gan
LWLijuan Wang
Lijuan Wang
YYYu Yu
Yu Yu
TNBG-5602, a novel anticancer drug candidate, may induce the expression of PPARγ, causing targeted lipotoxicity in cancer tissues. In this study, the in vivo metabolism in rats, in vitro metabolism in recombinant cytochromes, molecular docking for the CYP binding site, and pharmacokinetics in rats were explored to better understand TNBG-5602′s in vivo fate and behavior. Thirteen metabolites were identified using a high-resolution mass spectrometry method, and metabolizing pathways of TNBG-5602 were proposed. Results suggest that TNBG-5602 could be metabolized by CYP450s, while CYP2D6 may play an important role in its in vivo metabolism. The main metabolizing sites of TNBG-5602 are the amino group on the side chain and rings A and E in the molecule. TNBG-5602 is a potent CYP2D6 inhibitor, with an IC50 value of 2.52 μM. An interaction responsible for its metabolism is formed by the NH on the side chain bonding with the ASP301 on the CYP2D6. The pharmacokinetics in rats after a single intravenous administration were fitted to a two-compartment model. The clearance was 0.022 L min−1, and the elimination half-life was 710.9 min. The distribution volume of the peripheral compartment was 1.88-fold that of the central compartment, while the K12 was 1.5-fold that of K21. In conclusion, these studies have not only revealed the metabolizing pathways of TNBG-5602 using in vivo and in vitro methodology, but they have also provided the pharmacokinetic characteristics of TNBG-5602 in rats. The results suggest that TNBG-5602 has good drug developability in terms of pharmacokinetic behaviors.

9 June 2023 in Molecules
Verified
Journal Article
Open access
PDF file
LWLijuan Wang
Lijuan Wang
YDYongliang Ding
Yongliang Ding
QTQian Tang
Qian Tang
XNXiaodong Niu
Xiaodong Niu
Most injectable preparations for the articular cavity are solution-type preparations that are frequently administered because of rapid elimination. In this study, triptolide (TPL), an effective ingredient in the treatment of rheumatoid arthritis (RA), was prepared in the form of a nanoparticle thermosensitive gel (TPL-NS-Gel). The particle size distribution and gel structure were investigated by TEM, laser particle size analysis and laser capture microdissection. The effect of the nanoparticle carrier material PLGA on the phase transition temperature was investigated by 1H variable temperature NMR and DSC. The tissue distribution, pharmacokinetic behavior, four inflammatory factors and therapeutic effect were determined in a rat RA model. The results suggested that PLGA increased the gel phase transition temperature. The drug concentration of the TPL-NS-Gel group in joint tissues was higher than that in other tissues at different time points, and the retention time was longer than that of the TPL-NS group. After 24 days of administration, TPL-NS-Gel significantly improved the joint swelling and stiffness of the rat models, and the improvement degree was better than that of the TPL-NS group. TPL-NS-Gel significantly decreased the levels of hs-CRP, IL-1, IL-6 and TNF-α in serum and joint fluid. There was a significant difference between the TPL-NS-Gel and TPL-NS groups on Day 24 (p < 0.05). Pathological section results showed that inflammatory cell infiltration was lower in the TPL-NS-Gel group, and no other obvious histological changes were observed. Upon articular injection, the TPL-NS-Gel prolonged drug release, reduced the drug concentration outside the articular tissue and improved the therapeutic effect in a rat RA model. The TPL-NS-Gel can be used as a new type of sustained-release preparation for articular injection.

28 July 2021 in Current Pharmaceutical Analysis
Verified
Journal Article
Open access
PDF file
LWLijuan Wang
Lijuan Wang
YLYan Liu
Yan Liu
RLRui Li
Rui Li
DHDong Xian He
Dong Xian He
Objectives: Riptolide (TPL) has been shown to have a good clinical effect on rheumatoid arthritis (RA). We designed TPL microspheres (TPL-MS) and investigated its metabolic behavior in human, dog, rabbit and rat liver microsomes (HLM, DLM, RLM and SDRLM) with UPLC- MS/MS method. Methods: First, a UPLC-MS/MS method was established to measure the concentration of TPL in samples. The sample was separated on a C18 column (2.1×100 mm, 1.8μm) and eluted with a gradient elution. The precursor ions/product ions were m/z 378.1/361.0 for TPL and 260.0/116.2 for the internal standard. Then T1/2, Vmax and CLint were calculated from the above data. Finally, the metabolites of TPL-MS were identified by high-resolution UPLC-MS/MS. The sample was separated on a C18 column (2.1×100 mm, 2.2 μm) and eluted with isocratic elution. Mass spectrometric detection was carried out on a thermo Q-exactive mass spectrometer with HESI. The scanning range of precursor ions was from m/z 50 to m/z 750. Results: Through several indicators including standard curve, precision, accuracy, stability, matrix effect and recovery rate, the enzymatic kinetics parameters including T1/2, Vmax and CLint were evaluated. Several metabolites of TPL-MS were identified. Discussion: UPLC-MS/MS method is an accurate and sensitive method for the determination of TPL in liver microsome samples with good precision, accuracy and stability. The variation of parameters indicated that the microspheres can delay the elimination of TPL in liver microsomes. Conclusion: The metabolism of TPL-MS varied among species, but no new metabolites appeared.

1 October 2008 in Key Engineering Materials
Verified
Journal Article
Closed access
PDF file
LWLijuan Wang
Lijuan Wang
GYGuo Fu Yin
Guo Fu Yin
LXLei Xu
Lei Xu
Management of fixture design knowledge is vital for improving product quality and reducing product lead time, but there is no efficient and effective mechanism in current computer-aided fixture design systems to integrate fixture design process, to share design resource as well as acquisition and reuse knowledge. Ontology is increasingly seen as a key technology for enabling semantics-driven knowledge processing. On the background of a architecture of fixture design system based on knowledge introduced in the paper, we presented and expatiated a fixture design knowledge acquisition and reuse technology based on ontology, which embeds ontology in current computer-aided fixture design based on knowledge. Finally, the related case study was given.